REGN News

Class Action Alert: Levi & Korsinsky Reminds Regeneron (REGN) Investors of September 14, 2026 Deadline

REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of September 14, 2026 Deadline

Pomerantz LLP Issues Reminder to Shareholders in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit – REGN

Regeneron Announces Investor Conference Presentations

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Investor Alert: Deadline Approaching to Join Regeneron Pharmaceuticals, Inc. (REGN) Class Action - Contact Levi & Korsinsky

REGN EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026 Ready to Announce with Confidence?